Teli Liu

机构：Peking University, National Medical Products Administration, China People's Public Security University, Peking University Cancer Hospital · ORCID：0000-0002-7581-7707

发表论文 74 篇 · 总被引 1109 次 · h-index 18

代表论文

• Comparison of an Affibody-based Molecular Probe and 18 F-FDG for Detecting HER2-Positive Breast Cancer at PET/CT (2024 · Radiology · 被引 25)
• An iodine‑labelled Antibody–drug conjugate PET probe for noninvasive monitoring of Nectin-4 expression in urothelial carcinoma (2023 · International Journal of Pharmaceutics · 被引 18)
• Copper-64 Based PET-Radiopharmaceuticals: Ways to Clinical Translational (2024 · Seminars in Nuclear Medicine · 被引 17)
• Preparation and Application of a Bioorganic Nanoparticle-Enhanced PDL1-Targeted Small-Molecule Probe (2023 · ACS Applied Materials & Interfaces · 被引 14)
• Construction of an Iodine-Labeled CS1001 Antibody for Targeting PD-L1 Detection and Comparison with Low-Molecular-Peptide Micro-PET Imaging (2022 · Molecular Pharmaceutics · 被引 9)
• Preclinical evaluation and first in human study of Al18F radiolabeled ODAP-urea-based PSMA targeting ligand for PET imaging of prostate cancer (2022 · Frontiers in Oncology · 被引 9)